Publications

Developing a decision support tool for the continuation or deprescribing of antithrombotic therapy in patients receiving end-of-life care: Results of a European Delphi study
Isabelle Mahé et al. Thromb Research 2026 February

“Who am I to say that I’m not going to take it”: patient perspectives on decisions about antithrombotic therapy in the context of advanced cancer.
Elin Baddeley et al. Thromb Res. 2025 Sep:253:109399.
DOI: 10.1016/j.thromres.2025.109399. Epub 2025 Jul 6.
(WP 3 – patient perspective)

Anti-thrombotic therapy in patients with cancer at the end of life and associated clinical outcomes: A cohort study using population-linked routinely collected data
Sarah J. Aldridge et al. British Journal of Haematology. First published: 01 September 2025.
DOI.org/10.1111/bjh.70032
(WP2 – Welsh study); WP2 Utrecht study submitted; WP 2 Leiden study manuscript in preparation, results presented @ISTH; WP 2 combined paper predictors of adverse events in preparation, results presented @ISTH)

Shared decision-making and deprescribing to support anti-thrombotic therapy (dis)continuance for persons living with cancer in their last phase of life: A realist synthesis.
Justin Jagosh et al. PLoS Med. 2025 Aug 25;22(8):e1004663.
DOI: 10.1371/journal.pmed.1004663
(WP 1 – review)

Quality of vitamin K antagonist treatment during the last year of life.
Chantal Visser et al.
Hemasphere. 2025 May 19;9(5):e70135.
DOI: 10.1002/hem3.70135. eCollection 2025 May.
(WP 2 – Quality of vitamin K antagonist treatment)

Discontinuation of Anticoagulants and Occurrence of Bleeding and Thromboembolic Events in Vitamin K Antagonist Users with a Life-limiting Disease.
Eva K. Kempers et al. Thromb Haemost. 2025 Apr 4.
DOI: 10.1055/a-2524-5334. Online ahead of print.
(WP 2 – discontinuation of vitamin K antagonist treatment)

Understanding European patterns of deprescribing antithrombotic medication during end-of-life care in patients with cancer.
E.S.L. Martens et al., Thromb Res. 2025 Jan:245:109205.
DOI: 10.1016/j.thromres.2024.109205. Epub 2024 Nov 9.
(WP 1 – flash mob)

Use of antithrombotic therapy and the risk of cardiovascular outcomes and bleeding in cancer patients at the end of life: a Danish nationwide cohort study.
Mette Søgaard et al. J Thromb Haemost. 2025 Jan;23(1):190-200.
DOI: 10.1016/j.jtha.2024.09.023. Epub 2024 Oct 10.
(WP 2 – Danish study)

Towards optimal use of antithrombotic therapy of people with cancer at the end of life: A research protocol for the development and implementation of the SERENITY shared decision support tool.
Goedegebuur J et al. Thromb Res. 2023 Aug: 228:54-60.
DOI: 10.1016/j.thromres.2023.05.008